High rates of flares after anti‐tumor necrosis factor withdrawal in pediatric inflammatory bowel disease: A multi‐center study

OBJECTIVES: Outcomes of anti-tumor necrosis factor (anti-TNF) discontinuation in pediatric patients with inflammatory bowel disease (IBD) remain unclear. We aimed to quantify relapse and biologic re-initiation rates following anti-TNF withdrawal in patients in sustained clinical remission for at least 6 months. METHODS: Patients' characteristics were recorded at the time of anti-TNF discontinuation, at the time of flare, or at the end of follow-up, with a minimum follow-up of 1 year. A flare was defined as clinical, biochemical, or endoscopic activity leading to hospitalization, systemic corticosteroids, and/or initiation of a biologic. RESULTS: This multicenter retrospective study from the Pediatric IBD Porto Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) included 83 children from 21 centers (46 [55%] males, 59 Crohn's disease [CD], 24 ulcerative colitis [UC]), who discontinued anti-TNF. At the time of anti-TNF withdrawal, the median age was 14.8 years (interquartile range 12.4-16.9); 93% had biochemical remission, and 68% of those undergoing endoscopy were in endoscopic remission. Within 12 and 24 months, 45/83 (54%) and 56/74 (76%) experienced a flare, and 29/83 (35%) and 47/68 (69%) re-initiated a biologic, respectively. Overall, flare and biologic re-initiation rates were similar in CD and UC, between those with biochemical or endoscopic remission, and among those maintained on immunomodulators (n = 33) or 5-aminosalicylates (n = 20). Univariate and multivariable Cox models did not identify baseline predictors of relapse or biologic re-initiation. CONCLUSIONS: Discontinuing anti-TNF therapy in pediatric IBD patients in clinical remission is associated with high rates of disease flare and treatment re-initiation. This provides quantitative data to help balance the benefits and risks when considering anti-TNF withdrawal.

Authors

Institutions

Publication Details

Journal
Journal of Pediatric Gastroenterology and Nutrition
Published
2026-11-17
DOI
https://doi.org/10.1002/jpn3.70680
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

High rates of flares after anti‐tumor necrosis factor withdrawal in pediatric inflammatory bowel disease: A multi‐center study

Ben Kang, Patrizia Alvisi, Caterina Strisciuglio, Karl Mårild et al.
Journal of Pediatric Gastroenterology and Nutrition
Inflammatory Bowel Disease
article

High rates of flares after anti‐tumor necrosis factor withdrawal in pediatric inflammatory bowel disease: A multi‐center study

Ben Kang, Patrizia Alvisi, Caterina Strisciuglio, Karl Mårild, Paulina Krawiec, Ramit Magen‐Rimon, Jarosław Kierkuś, Iva Hojsak, Helena J. Rolandsdotter, Kaija‐Leena Kolho, Maya Granot, Laura Gianolio, Firas Rinawi, Richard Kay Russell, Saverio Pochesci, Anat Yerushalmy‐Feler, Lissy de Ridder, Yael Haberman, Assaf Hoofien, Salvatore Oliva, Bénédicte Pigneur, Marta Velasco Rodríguez‐Belvís, Dror S. Shouval, Batia Weiss, Anouk E Camman
article en

Abstract

OBJECTIVES: Outcomes of anti-tumor necrosis factor (anti-TNF) discontinuation in pediatric patients with inflammatory bowel disease (IBD) remain unclear. We aimed to quantify relapse and biologic re-initiation rates following anti-TNF withdrawal in patients in sustained clinical remission for at least 6 months. METHODS: Patients' characteristics were recorded at the time of anti-TNF discontinuation, at the time of flare, or at the end of follow-up, with a minimum follow-up of 1 year. A flare was defined as clinical, biochemical, or endoscopic activity leading to hospitalization, systemic corticosteroids, and/or initiation of a biologic. RESULTS: This multicenter retrospective study from the Pediatric IBD Porto Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) included 83 children from 21 centers (46 [55%] males, 59 Crohn's disease [CD], 24 ulcerative colitis [UC]), who discontinued anti-TNF. At the time of anti-TNF withdrawal, the median age was 14.8 years (interquartile range 12.4-16.9); 93% had biochemical remission, and 68% of those undergoing endoscopy were in endoscopic remission. Within 12 and 24 months, 45/83 (54%) and 56/74 (76%) experienced a flare, and 29/83 (35%) and 47/68 (69%) re-initiated a biologic, respectively. Overall, flare and biologic re-initiation rates were similar in CD and UC, between those with biochemical or endoscopic remission, and among those maintained on immunomodulators (n = 33) or 5-aminosalicylates (n = 20). Univariate and multivariable Cox models did not identify baseline predictors of relapse or biologic re-initiation. CONCLUSIONS: Discontinuing anti-TNF therapy in pediatric IBD patients in clinical remission is associated with high rates of disease flare and treatment re-initiation. This provides quantitative data to help balance the benefits and risks when considering anti-TNF withdrawal.

Journal of Pediatric Gastroenterology and Nutrition
Medical University of Lublin (PL), Cincinnati Children's Hospital Medical Center (US), Hôpital Necker-Enfants Malades (FR), University of Helsinki (FI), Tel Aviv University (IL), Technion – Israel Institute of Technology (IL), University of Zagreb (HR), University of Milan (IT), University of Campania "Luigi Vanvitelli" (IT), Université Paris Cité (FR), Emek Medical Center (IL), Tel Aviv Sourasky Medical Center (IL), Sheba Medical Center (IL), Leiden University Medical Center (NL), Kaplan Medical Center (IL), Policlinico Umberto I (IT), Helsinki University Hospital (FI), Rambam Health Care Campus (IL), Erasmus MC (NL), Karolinska Institutet (SE), Kyungpook National University (KR), Helsinki Children's Hospital (FI), Stockholm South General Hospital (SE), Assistance Publique – Hôpitaux de Paris (FR), Ospedale Maggiore Carlo Alberto Pizzardi (IT), Schneider Children's Medical Center (IL), Hospital Infantil Universitario Niño Jesús (ES), Children's Memorial Health Institute (PL), Rappaport Family Institute for Research in the Medical Sciences (IL), Sachs' Children and Youth Hospital (SE), Willem-Alexander Kinderziekenhuis (NL), Children's Hospital Zagreb (HR), Ospedale dei Bambini Vittore Buzzi (IT), Erasmus MC - Sophia Children’s Hospital (NL), Edmond and Lily Safra Children's Hospital (IL), University of Cincinnati (US), Sapienza University of Rome (IT)
Leona M. and Harry B. Helmsley Charitable Trust, Israel Science Foundation, Tel Aviv University, European Research Council
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon